吕万良 教授

研究领域: 药剂学
电话: +86-10-82802683
联系邮箱: [email protected]

个人简历

男，1966 年出生。北京大学教授、博士生导师、北京大学药学院党委副书记、药剂学系副主任、北京大学医学部纪委委员、北京大学医学部工会副主席。中国药学会药剂专业委员会副主任委员、中国颗粒学会常务理事；北京大学学报、中国新药杂志、中国药学杂志、BioMed Res. Int.等国内外学术期刊编委。从事肿瘤耐药性与药物递送系统生物药剂学研究。发表了研究论文150 余篇，部分论文发表于Biomaterials、J. Control. Release、Oncotarget 等药剂学科领域国际顶尖学术期刊上，近年获新药证书1 项、新药临床研究批件4 项；授权专利8 项；参编全国统编教材10 余部；获2009 年度教育部自然科学一等奖（第1 完成人）、2012 年度教育部自然科学一等奖（第2 完成人）等；培养的博士生获北京大学优秀博士论文奖6 项。

主要研究领域

1.肿瘤及其耐药靶标导向性载体药物传递系统的研究

2.药物新制剂研究

代表性论文

1. Zhang CX, Zhao WY, Liu L, Ju RJ, Mu LM, Zhao Y, Zeng F, Xie HJ, Yan Y, Lu WL*. A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment. Oncotarget. 2015;20;6(32):32681-700. (IF=6.359)

2. Zeng F, Ju RJ, Liu L, Xie HJ, Mu LM, Zhao Y, Yan Y, Hu YJ, Wu JS, Lu WL*. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer. Oncotarget 2015; 3;6(34):36625-42. (IF=6.359)

3. Shi JF, Sun MG, Li XY, Zhao Y, Ju RJ, Mu LM, Yan Y, Li XT, Zeng F, Lu WL*. A Combination of Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes for Treating Invasive Breast Cancer. J Biomed Nanotech. 2015;11(9): 1568-1582. (IF=5.338)

4. Sun MG, Shi JF, Li XY, Zhao Y. Ju RJ, Mu LM, Yan Y, Li XT, Zeng F, Lu WL*. Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer. J Biomed Nanotech. 2015;11(8): 1339–1353. (IF=5.338)

5. Zeng F, Ju RJ, Li XT, Lu WL*. Advances in investigations on the mechanism of cancer multidrug resistance and the liposomes-based treatment strategy. Journal of Pharmaceutical Investigation. December 2014 Dec; 44(7): 493-504.

6. Ju RJ, Li XT, Shi JF, Li XY, Sun MG, Zeng F, Zhou J, Liu L, Zhang CX, Zhao WY, Lu WL*. Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials. 2014 Aug;35(26):7610-21. (IF=8.557)

7. Li XY, Zhao Y, Sun MG, Shi JF, Ju RJ, Zhang CX, Li XT, Zhao WY, Mu LM, Zeng F, Lou JN, Lu WL*. Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma. Biomaterials. 2014 Jul;35(21):5591-604. (IF=8.557)

8. Li XT, Ju RJ, Li XY, Zeng F, Shi JF, Liu L, Zhang CX, Sun MG, Lou JN, Lu WL*. Multifunctional targeting daunorubicin plus quinacrine liposomes, modified by wheat germ agglutinin and tamoxifen, for treating brain glioma and glioma stem cells. Oncotarget. 2014 Aug 15;5(15):6497-511. (IF=6.359)

9. Ju RJ, Mu LM, Lu WL*. Research Spotlight: Targeting drug delivery systems for circumventing multidrug resistance of cancers. Ther Deliv. 2013 Jun;4(6):667-71

10. Ma X, Zhou J, Zhang CX, Li XY, Li N, Ju RJ, Shi JF, Sun MG, Zhao WY, Mu LM, Yan Y, Lu WL*. Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. Biomaterials. 2013 Jun;34(18):4452-65. (IF=8.312)

11. Zhou J, Zhao WY, Ma X, Ju RJ, Li XY, Li N, Sun MG, Shi JF, Zhang CX, Lu WL*.The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials. 2013 May;34(14):3626-38. (IF=8.312)

12. Li N, Zhang CX, Wang XX, Zhang L, Ma X, Zhou J, Ju RJ, Li XY, Zhao WY, Lu WL*. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways. Biomaterials. 2013 Apr;34(13):3366-80. (IF=8.312)

13. Li Y, He H, Jia X*, Lu WL*, Lou J, Wei Y. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials. 2012 May;33(15):3899-908. (IF=7.604)

14. Yu Y, Wang ZH, Zhang L, Yao HJ, Zhang Y, Li RJ, Ju RJ, Wang XX, Zhou J, Li N, Lu WL*. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. Biomaterials. 2012 Feb; 33(6):1808-20. (IF=7.604)

15. Zhang L, Yao HJ, Yu Y, Zhang Y, Li RJ, Ju RJ, Wang XX, Sun MG, Shi JF, Lu WL*. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials. 2012 Jan;33(2):565-82. (7.604)

16. Ju RJ, Huang RJ, Zhou J, Li RJ, Zhou P, Zhang ZH, Xiang FJ, Xu DJ, Liu WX, Ma XT, Zhang Q, Lu WL*. Separation of injectable salidroside by column chromatography of macroporous resins for treating myocardial ischemia. Science China Chemistry, 2012, 55(7): 1435–1444. (IF=1.327)

17. Men Y, Wang XX, Li RJ, Zhang Y, Tian W, Yao HJ, Ju RJ, Ying X, Zhou J, Li N, Zhang L, Yu Y, Lu WL*. The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals. Int J Nanomedicine. 2011;6:3125-37. (IF=3.130)

18. Wang XX, Li YB, Yao HJ, Ju RJ, Zhang Y, Li RJ, Yu Y, Zhang L, Lu WL*. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials. 2011 Aug;32(24):5673-87. (IF=7.404)

19. Yao HJ, Ju RJ, Wang XX, Zhang Y, Li RJ, Yu Y, Zhang L, Lu WL*. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials. 2011 Feb; 32:3285-3302. (IF=7.404)

20. Ying X, Wen H, Yao HJ, Zhang Y, Tian W, Zhang L, Ju RJ, Wang XX, Yu Y, Lu WL*. Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice. Pharmacology. 2011 Feb 1;87(1-2):105-114. (IF=1.788)

21. Zhang Y, Ying X, Tian W, Li RJ, Yao HJ, Men Y, Yu Y, Zhang L, Ju RJ, Wang XX, Zhou J, Chen JX, Li N, Lu WL*. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer. Mol Pharm. 2011 Feb 7;8(1):162-75. (IF=4.782)

22. Li RJ, Ying X, Zhang Y, Ju RJ, Wang XX, Yao HJ, Men Y, Tian W, Yu Y, Zhang L, Huang RJ, Lu WL*. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J Control Release. 2011 Feb , 149(3):281-291. (IF=6.499)

科研项目